Abstract: A dual stage pressure relief valve for relieving pressure. The pressure relief valve includes a main body, a poppet bulb, a pilot piston, and a poppet cap. The main body defines a main channel that extends from a first opening to a second opening. The poppet bulb defines a first flow channel being in fluid communication with the main channel. The pilot piston defines a reset channel in fluid communication with the first flow channel of the poppet bulb. The cap channel has a diameter that is greater than a diameter of the reset channel. The poppet cap defines a cap channel in fluid communication with the reset channel of the pilot piston and with a pressure cavity defined by the poppet cap and an end of the main body.

Abstract: A dual stage pressure relief valve for relieving pressure. The pressure relief valve includes a main body, a poppet bulb, a pilot piston, and a poppet cap. The main body defines a main channel that extends from a first opening to a second opening. The poppet bulb defines a first flow channel being in fluid communication with the main channel. The pilot piston defines a reset channel in fluid communication with the first flow channel of the poppet bulb. The cap channel has a diameter that is greater than a diameter of the reset channel. The poppet cap defines a cap channel in fluid communication with the reset channel of the pilot piston and with a pressure cavity defined by the poppet cap and an end of the main body.

Abstract: An in-flight refueling hose and method. The hose includes an inner braid including pseudoelastic shape memory alloy (e.g., nitinol) wires. These wires undergo a stress induced phase change absorbing energy to dampen oscillations of the hose in use.

Abstract: A sprinkler head including a sprinkler body with a passage for fluid and a seal mechanism sealing the passage, and a cage member. A frangible bulb extends between the cage member and the seal. A shape memory alloy element is associated with the frangible bulb and has a first configuration that fits within, about, or abutting the bulb and a second configuration at a predetermined temperature which breaks the frangible bulb releasing the fluid through the passage.

Abstract: An in-flight refueling hose and method. The hose includes an inner braid including pseudoelastic shape memory alloy (e.g., nitinol) wires. These wires undergo a stress induced phase change absorbing energy to dampen oscillations of the hose in use.

Abstract: A sprinkler head including a sprinkler body with a passage for fluid and a seal mechanism sealing the passage, and a cage member. A frangible bulb extends between the cage member and the seal. A shape memory alloy element is associated with the frangible bulb and has a first configuration that fits within, about, or abutting the bulb and a second configuration at a predetermined temperature which breaks the frangible bulb releasing the fluid through the passage.

Abstract: This invention provides liposomic composition, containing as active ingredient (-)-N-.alpha.-dimethyl-N-(2-propynylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0.1-40% by weight of selegilin and/or a salt thereof, 2 to 40% by weight of lipids, preferably phospholipids, 0 to 10% by weight of cholesterol, 0 to 20% by weight of an alcohol, 0 to 25% by weight of a glycol, 0 to 3% by weight of an antioxidant, 0 to 3% by weight of a preserving agent, 0 to 2% by weight of a viscosity influencing agent, 0 to 50% by weight of cyclodextrin or a cyclodextrin derivative and 30 to 90% by weight of water. This invention relates to pharmaceutical composition, containing the liposomic composition described and if desired, usual filling and diluting agents and other auxiliaries, preferably in oral, parenteral or transdermal form. This invention provides the process for the preparation of liposomic compositions containing selegilin and/or salt thereof.

Abstract: The invention relates to two phase pharmaceutical compositions comprising as active ingredient a MAO inhibitor and an uptake inhibitor together with usual pharmaceutical auxiliaries. The compositions can be used for the treatment of neurodegenerative diseases. As active ingredient optionally N-(1-phenyl-isopropyl)-N-methyl-propinylamine or N-(4-fluoro-phenyl)-isoprop-1-yl-N-methyl-propinylamine or their salts, optically active isomers or metabolites are used both as MAO inhibitor and as uptake inhibitor.

Abstract: An anhydrous transdermal composition is disclosed comprising in a 20 to 100% lyotropic liquid crystalline arrangement:5 to 15 weight % of optically active or racemic N-methyl-N-(1-phenyl-2-propyl)-2-propynylamine or N-methyl-N-{1-(4-fluorophenyl)-2-propyl}-2-propynylamine or a pharmaceutically acceptable salt thereof;40 to 70% by weight of liquid polyethylene glycol;10 to 20% by weight of solid polyethylene glycol;2 to 30% by weight of a nonionic surface active agent;2 to 20% by weight of propylene glycol, and if desired,0.5 to 2% by weight of a polymer, the a value of which is greater than 0.6, andoptionally, in an amount needed up to 100% an emulsifying agent.

Abstract: This invention relates to a primycin-containing colloidal basic gel comprising 5-30% of primycin and 95-70% of N-methyl-pyrrolidone-2. The invention also relates to antibacterial compositions particularly for the treatment of acne vulgaris comprising as active ingredient 0.1-100% of a primycin-containing colloidal basic gel, if desired together with further antimicrobial active ingredients, in admixture with 99.9-0% of usual inert pharmaceutical filling, diluting and other formulating additives. The invention also relates to combination composition comprising as active ingredient 1-60% of a primycin-containing colloidal basic gel and 0.1-40% of further pharmaceutical active ingredient(s), e.g. one or more antibiotic(s), chemotherapeutical agent(s), fungistatic or fungicidal agent(s), steroidal or non-steroidal antiinflammatory agent (s), epithelogenic agent(s), local anaesthetic(s), and/or vitamin(s).

Abstract: N,N,N-trimethyl-2-hydroxyethyl-ammonium-[1-ethyl-6-fluoro-4-oxo-7-(1-pipera zinyl)-1,4-dihydro-quinolizine-3-carboxylate] of the formula I ##STR1## as a norfloxacin antimicrobial salt capable of enteral administration.

Abstract: The present invention relates to synergistic pharmaceutical compositions for the treatment of liver disorders comprising 5-aminoimidazole-4-carboxamide orthophosphate (AICA-phosphate) as active ingredient in association with vitamins, preferably with vitamin B and/or E and optionally with other pharmaceutical excipients.